Stargardt Disease clinical trials at University of California Health
2 research studies open to eligible people
Showing trials for
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
open to eligible people ages 8-70
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD
at UCLA
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
open to eligible people ages 18-60
To evaluate the safety and efficacy of Zimura™ (complement factor C5 inhibitor) compared to Sham in subjects with autosomal recessive Stargardt disease 1 (STGD1).
at UCLA
Our lead scientists for Stargardt Disease research studies include Michael Gorin, MD, PhD.
Last updated: